TICAGRELOR | A208576 | ALEMBIC PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AstraZeneca AB et al v. Alembic Pharmaceuticals Ltd. et al 1 patentANDA 208576ticagrelor | D. Del. | 2022-09-16 | Terminated 2022-12-30 | — |
AstraZeneca LP et al v. Alembic Pharmaceuticals LTD et al. 1 patentANDA 208576ticagrelor | D. Del. | 2015-10-30 | Terminated 2015-11-12 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.3240
per ea
Lowest NADAC/Unit
$0.2836
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62332050060TICAGRELOR 60 MG TABLET | $0.3240 | EA | Generic | — | 2026-06-17 |
| 62332024160TICAGRELOR 90 MG TABLET | $0.2836 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.